secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001649094-24-000096
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on
--------------------------------------------------------------------

- Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.
- Cash, equivalents and investments $3,273M as of Sep 30, 2024, up from $1,243M at Dec 31, 2023.
- VAX-31 Phase 1/2 topline positive: met non-inferiority vs PCV20 for all 20 shared serotypes at middle/high doses.
- VAX-31 selected for Phase 3 adult program; pivotal non-inferiority study initiation expected by mid-2025.
- VAX-24 infant Phase 2 primary series topline data expected by end of Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909424000096/0001649094-24-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909424000096/pcvx-20241105.htm
  HTML page:      https://secwatch.observer/filing/0001649094-24-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer